Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
A Phase I Study, With Expanded Cohort, of Biweekly Fixed-dose Rate Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic and Biliary Carcinomas
Sponsor: National Comprehensive Cancer Network
A PHASE1 clinical study on Biliary Cancer and Pancreatic Cancer, this trial is completed. The trial is conducted by National Comprehensive Cancer Network and has accumulated 6 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Comprehensive Cancer Network
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .